Go Pro
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free NMTC Stock Alerts

NeuroOne Medical Technologies (NMTC) Competitors

NeuroOne Medical Technologies logo
$3.29 -0.05 (-1.56%)
As of 10:52 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NMTC vs. NNOX, PYPD, VANI, SPAI, and LAKE

Should you buy NeuroOne Medical Technologies stock or one of its competitors? MarketBeat compares NeuroOne Medical Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroOne Medical Technologies include Nano-X Imaging (NNOX), PolyPid (PYPD), Vivani Medical (VANI), Safe Pro Group (SPAI), and Lakeland Industries (LAKE). These companies are all part of the "medical equipment" industry.

How does NeuroOne Medical Technologies compare to Nano-X Imaging?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

NeuroOne Medical Technologies has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

NeuroOne Medical Technologies has higher earnings, but lower revenue than Nano-X Imaging. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$9.72M2.94-$3.61M-$0.85N/A
Nano-X Imaging$13.02M7.45-$75.02M-$1.58N/A

NeuroOne Medical Technologies has a net margin of -68.35% compared to Nano-X Imaging's net margin of -716.44%. Nano-X Imaging's return on equity of -70.96% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-68.35% -99.43% -70.40%
Nano-X Imaging -716.44%-70.96%-62.26%

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NeuroOne Medical Technologies presently has a consensus target price of $11.67, indicating a potential upside of 254.83%. Nano-X Imaging has a consensus target price of $5.00, indicating a potential upside of 258.68%. Given Nano-X Imaging's stronger consensus rating and higher probable upside, analysts plainly believe Nano-X Imaging is more favorable than NeuroOne Medical Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Nano-X Imaging
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
3 Strong Buy rating(s)
3.00

In the previous week, Nano-X Imaging had 33 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 35 mentions for Nano-X Imaging and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Nano-X Imaging's score of 0.05 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroOne Medical Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nano-X Imaging
1 Very Positive mention(s)
3 Positive mention(s)
24 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Nano-X Imaging beats NeuroOne Medical Technologies on 11 of the 17 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to PolyPid?

PolyPid (NASDAQ:PYPD) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

26.5% of PolyPid shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PolyPid has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -99.43% beat PolyPid's return on equity.

Company Net Margins Return on Equity Return on Assets
PolyPidN/A -241.96% -126.91%
NeuroOne Medical Technologies -68.35%-99.43%-70.40%

NeuroOne Medical Technologies has higher revenue and earnings than PolyPid. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolyPidN/AN/A-$34.17M-$1.91N/A
NeuroOne Medical Technologies$9.72M2.94-$3.61M-$0.85N/A

In the previous week, PolyPid had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for PolyPid and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat PolyPid's score of 0.68 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PolyPid
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeuroOne Medical Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

PolyPid has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

PolyPid currently has a consensus target price of $11.67, indicating a potential upside of 133.47%. NeuroOne Medical Technologies has a consensus target price of $11.67, indicating a potential upside of 254.83%. Given NeuroOne Medical Technologies' higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than PolyPid.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PolyPid
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

PolyPid beats NeuroOne Medical Technologies on 8 of the 15 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Vivani Medical currently has a consensus target price of $3.75, suggesting a potential upside of 214.33%. NeuroOne Medical Technologies has a consensus target price of $11.67, suggesting a potential upside of 254.83%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Vivani Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vivani Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Vivani Medical has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -99.43% beat Vivani Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Vivani MedicalN/A -264.04% -79.85%
NeuroOne Medical Technologies -68.35%-99.43%-70.40%

In the previous week, Vivani Medical had 4 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 6 mentions for Vivani Medical and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Vivani Medical's score of 0.70 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vivani Medical
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeuroOne Medical Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NeuroOne Medical Technologies has higher revenue and earnings than Vivani Medical. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vivani MedicalN/AN/A-$26.61M-$0.40N/A
NeuroOne Medical Technologies$9.72M2.94-$3.61M-$0.85N/A

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 53.3% of Vivani Medical shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vivani Medical has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Summary

NeuroOne Medical Technologies beats Vivani Medical on 9 of the 15 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Safe Pro Group?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Safe Pro Group (NASDAQ:SPAI) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

NeuroOne Medical Technologies has higher revenue and earnings than Safe Pro Group. Safe Pro Group is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroOne Medical Technologies$9.72M2.94-$3.61M-$0.85N/A
Safe Pro Group$610K141.78-$14.32M-$0.71N/A

NeuroOne Medical Technologies presently has a consensus target price of $11.67, suggesting a potential upside of 254.83%. Safe Pro Group has a consensus target price of $10.00, suggesting a potential upside of 141.55%. Given NeuroOne Medical Technologies' higher probable upside, equities analysts plainly believe NeuroOne Medical Technologies is more favorable than Safe Pro Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Safe Pro Group
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.80

In the previous week, Safe Pro Group had 6 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 8 mentions for Safe Pro Group and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Safe Pro Group's score of 0.75 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NeuroOne Medical Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Safe Pro Group
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

NeuroOne Medical Technologies has a net margin of -68.35% compared to Safe Pro Group's net margin of -800.91%. NeuroOne Medical Technologies' return on equity of -99.43% beat Safe Pro Group's return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroOne Medical Technologies-68.35% -99.43% -70.40%
Safe Pro Group -800.91%-119.17%-107.17%

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 54.8% of Safe Pro Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NeuroOne Medical Technologies has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Safe Pro Group has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market.

Summary

NeuroOne Medical Technologies beats Safe Pro Group on 10 of the 17 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Lakeland Industries?

Lakeland Industries (NASDAQ:LAKE) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Lakeland Industries currently has a consensus target price of $16.00, suggesting a potential upside of 44.53%. NeuroOne Medical Technologies has a consensus target price of $11.67, suggesting a potential upside of 254.83%. Given NeuroOne Medical Technologies' higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Lakeland Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakeland Industries
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
NeuroOne Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Lakeland Industries had 3 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 5 mentions for Lakeland Industries and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Lakeland Industries' score of 0.44 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakeland Industries
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
NeuroOne Medical Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lakeland Industries has a net margin of -10.87% compared to NeuroOne Medical Technologies' net margin of -68.35%. Lakeland Industries' return on equity of -6.64% beat NeuroOne Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Lakeland Industries-10.87% -6.64% -4.13%
NeuroOne Medical Technologies -68.35%-99.43%-70.40%

NeuroOne Medical Technologies has lower revenue, but higher earnings than Lakeland Industries. Lakeland Industries is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakeland Industries$192.65M0.57-$25.31M-$2.13N/A
NeuroOne Medical Technologies$9.72M2.94-$3.61M-$0.85N/A

71.7% of Lakeland Industries shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 3.4% of Lakeland Industries shares are owned by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lakeland Industries has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Summary

Lakeland Industries and NeuroOne Medical Technologies tied by winning 7 of the 14 factors compared between the two stocks.

Get NeuroOne Medical Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTC vs. The Competition

Export
MetricNeuroOne Medical TechnologiesMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$28.58M$9.36B$6.84B$12.34B
Dividend YieldN/A1.67%2.67%6.11%
P/E Ratio-3.8626.0225.8724.19
Price / Sales2.9417.18553.99100.49
Price / CashN/A14.9229.0936.93
Price / Book3.875.9910.796.42
Net Income-$3.61M$179.69M$3.58B$337.00M
7 Day Performance1.17%5.47%2.49%0.94%
1 Month Performance-7.38%4.69%0.21%-0.66%
1 Year Performance-19.41%15.93%35.20%27.96%

NeuroOne Medical Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTC
NeuroOne Medical Technologies
2.6065 of 5 stars		$3.29
-1.6%		$11.67
+254.8%		-18.1%$28.58M$9.72MN/A20
NNOX
Nano-X Imaging
3.7603 of 5 stars		$1.51
-6.8%		$5.00
+231.1%		-79.2%$112.74M$13.02MN/A190
PYPD
PolyPid
2.7373 of 5 stars		$4.99
-2.7%		$11.67
+133.8%		+33.1%$97.90MN/AN/A80
VANI
Vivani Medical
3.4427 of 5 stars		$1.19
+5.3%		$3.75
+215.1%		-9.1%$97.45MN/AN/A20
SPAI
Safe Pro Group
2.9472 of 5 stars		$4.43
-4.9%		$10.00
+125.7%		+53.2%$97.32M$610KN/A11

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMTC) was last updated on 6/29/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel